Harald Zeisler1, Elisa Llurba, Frédéric Chantraine, Manu Vatish, Anne Cathrine Staff, Maria Sennström, Matts Olovsson, Shaun P Brennecke, Holger Stepan, Deirdre Allegranza, Carina Dinkel, Maria Schoedl, Peter Dilba, Martin Hund, Stefan Verlohren. 1. Department of Obstetrics and Gynecology, Medical University Vienna, Vienna, Austria; the Department of Obstetrics, Maternal-Fetal Medicine Unit, Hospital Universitari Vall d'Hebron, and the Maternal and Child Health and Development Network (SAMID) RD12/0026, Instituto de Salud Carlos III, Barcelona, Spain; the Department of Obstetrics and Gynecology, University of Liege, CHR de la Citadelle, Liege, Belgium; Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom (previously University Hospitals National Health Service Trust, Coventry, United Kingdom, during the conduct of the study); the Departments of Gynecology and Obstetrics, Oslo University Hospital and University of Oslo, Oslo, Norway; the Department of Women's and Children's Health, Karolinska University Hospital, Karolinska Institute, Stockholm, and the Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden; the Pregnancy Research Centre, Department of Maternal-Fetal Medicine, Royal Women's Hospital and Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia; the Department of Obstetrics, University of Leipzig, Leipzig, Roche Diagnostics GmbH, Penzberg, and the Department of Obstetrics, Charité Universitätsmedizin, Berlin, Germany; and Roche Diagnostics International, Rotkreuz, Switzerland.
Abstract
OBJECTIVE: To assess the association of a serum soluble fms-like tyrosine kinase 1-to-placental growth factor (sFlt-1-to-PlGF) ratio of greater than 38 with time to delivery and preterm birth. METHODS: Secondary analysis of an observational cohort study that included women 18 years of age or older from 24 to 36 6/7 weeks of gestation at their first study visit with suspected (not confirmed) preeclampsia. Participants were recruited from December 2010 to January 2014 at 30 sites in 14 countries. A total of 1,041 women were included in time-to-delivery analysis and 848 in preterm birth analysis. RESULTS: Women with an sFlt-1-to-PlGF ratio greater than 38 (n=250) had a 2.9-fold greater likelihood of imminent delivery (ie, delivery on the day of the test) (Cox regression hazard ratio 2.9; P<.001) and shorter remaining time to delivery (median 17 [interquartile range 10-26] compared with 51 [interquartile range 30-75] days, respectively; Weibull regression factor 0.62; P<.001) than women with an sFlt-1-to-PlGF ratio of 38 or less, whether or not they developed preeclampsia. For women who did not (n=842) and did develop preeclampsia (n=199), significant correlations were seen between an sFlt-1-to-PlGF ratio greater than 38 and preterm birth (r=0.44 and r=0.46; both P<.001). Among women who did not develop preeclampsia, those who underwent iatrogenic preterm delivery had higher median sFlt-1-to-PlGF ratios at their first visit (35.3, interquartile range 6.8-104.0) than those who did not (8.4, interquartile range 3.4-30.6) or who delivered at term (4.3, interquartile range 2.4-10.9). CONCLUSIONS: In women undergoing evaluation for suspected preeclampsia, a serum sFlt-1-to-PlGF ratio greater than 38 is associated with a shorter remaining pregnancy duration and a higher risk of preterm delivery.
OBJECTIVE: To assess the association of a serum soluble fms-like tyrosine kinase 1-to-placental growth factor (sFlt-1-to-PlGF) ratio of greater than 38 with time to delivery and preterm birth. METHODS: Secondary analysis of an observational cohort study that included women 18 years of age or older from 24 to 36 6/7 weeks of gestation at their first study visit with suspected (not confirmed) preeclampsia. Participants were recruited from December 2010 to January 2014 at 30 sites in 14 countries. A total of 1,041 women were included in time-to-delivery analysis and 848 in preterm birth analysis. RESULTS:Women with an sFlt-1-to-PlGF ratio greater than 38 (n=250) had a 2.9-fold greater likelihood of imminent delivery (ie, delivery on the day of the test) (Cox regression hazard ratio 2.9; P<.001) and shorter remaining time to delivery (median 17 [interquartile range 10-26] compared with 51 [interquartile range 30-75] days, respectively; Weibull regression factor 0.62; P<.001) than women with an sFlt-1-to-PlGF ratio of 38 or less, whether or not they developed preeclampsia. For women who did not (n=842) and did develop preeclampsia (n=199), significant correlations were seen between an sFlt-1-to-PlGF ratio greater than 38 and preterm birth (r=0.44 and r=0.46; both P<.001). Among women who did not develop preeclampsia, those who underwent iatrogenic preterm delivery had higher median sFlt-1-to-PlGF ratios at their first visit (35.3, interquartile range 6.8-104.0) than those who did not (8.4, interquartile range 3.4-30.6) or who delivered at term (4.3, interquartile range 2.4-10.9). CONCLUSIONS: In women undergoing evaluation for suspected preeclampsia, a serum sFlt-1-to-PlGF ratio greater than 38 is associated with a shorter remaining pregnancy duration and a higher risk of preterm delivery.
Authors: Ulla Sovio; Francesca Gaccioli; Emma Cook; Martin Hund; D Stephen Charnock-Jones; Gordon C S Smith Journal: Hypertension Date: 2017-02-06 Impact factor: 10.190
Authors: Ana Sofia Cerdeira; Joe O'Sullivan; Eric O Ohuma; Deborah Harrington; Pawel Szafranski; Rebecca Black; Lucy Mackillop; Lawrence Impey; Catherine Greenwood; Tim James; Ian Smith; Aris T Papageorghiou; Marian Knight; Manu Vatish Journal: Hypertension Date: 2019-08-12 Impact factor: 10.190
Authors: Marcos Augusto Bastos Dias; Leandro De Oliveira; Arundhanthi Jeyabalan; Beth Payne; Christopher W Redman; Laura Magee; Lucilla Poston; Lucy Chappell; Paul Seed; Peter von Dadelszen; James Michael Roberts Journal: BMC Pregnancy Childbirth Date: 2019-10-07 Impact factor: 3.007
Authors: Lindsay Armstrong-Buisseret; Eleanor Mitchell; Trish Hepburn; Lelia Duley; Jim G Thornton; Tracy E Roberts; Claire Storey; Rebecca Smyth; Alexander E P Heazell Journal: Trials Date: 2018-10-01 Impact factor: 2.279